An Y-S, Lee D H, Yoon J-K, Lee S J, Kim T H, Kang D K, Kim K S, Jung Y S, Yim H
Young-Sil An, M.D., Ph.D., Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Ajou University, Woncheon-dong, Yeongtong-gu, Gyeonggi-do, Suwon, Korea 443-749, Tel. +82/31/219 59 48; Fax +82/31/219 59 50, E-mail:
Nuklearmedizin. 2014;53(3):89-94. doi: 10.3413/Nukmed-0605-13-06. Epub 2013 Nov 13.
The aim of this study was to evaluate the diagnostic abilities of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography(PET/CT) compared with those of ultrasonography and magnetic resonance imaging (MRI) for axillary lymph node staging in breast cancer patients.
PATIENTS, METHODS: Preoperative 18F-FDG PET/non-contrast CT, ultrasonography and MRI were performed in 215 women with breast cancer. Axillary lymph node dissection was performed in all patients and the diagnostic performance of each modality was evaluated using histopathologic assessments as the reference standard. ROC curves were compared to evaluate the diagnostic ability of several imaging modalities (i. e., ultrasonography, MRI and 18F-FDG PET/CT).
In total, 132 patients (61.4%) had axillary lymph node metastasis. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for the detection of axillary lymph node metastasis were 72.3%, 77.3%, 66.7%, 81.6%, 75.3% for ultrasonography, 67.5%, 78.0%, 65.9%, 79.2%, 74.0% for MRI, and 62.7%, 88.6%, 77.6%, 79.1%, 78.6% for 18F-FDG PET/CT, respectively. There was no significant difference in diagnostic ability among the imaging modalities (i.e., ultrasonography, MRI and 18F-FDG PET/CT). The diagnostic ability of 18F-FDG PET/CT was significantly improved by combination with MRI (p = 0.0002) or ultrasonography (p < 0.0001). The combination of 18F-FDG PET/CT with ultrasonography had a similar diagnostic ability to that of all three modalities combined (18F-FDG PET/CT+ultrasonography+MRI, p = 0.05).
The diagnostic performance of 18F-FDG PET/CT for detection of axillary node metastasis was not significantly different from that of ultrasonography or MRI in breast cancer patients. Combining 18F-FDG PET/CT with ultrasonography or MRI could improve the diagnostic performance compared to 18F-FDG PET/CT alone.
本研究的目的是评估18F-氟脱氧葡萄糖(FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)与超声检查和磁共振成像(MRI)相比,在乳腺癌患者腋窝淋巴结分期中的诊断能力。
患者、方法:对215例乳腺癌女性患者进行术前18F-FDG PET/非增强CT、超声检查和MRI检查。所有患者均行腋窝淋巴结清扫术,并以组织病理学评估作为参考标准,评估每种检查方法的诊断性能。比较ROC曲线以评估几种成像检查方法(即超声检查、MRI和18F-FDG PET/CT)的诊断能力。
共有132例患者(61.4%)发生腋窝淋巴结转移。超声检查检测腋窝淋巴结转移的敏感性、特异性、阳性预测值、阴性预测值和准确性分别为72.3%、77.3%、66.7%、81.6%、75.3%;MRI分别为67.5%、78.0%、65.9%、79.2%、74.0%;18F-FDG PET/CT分别为62.7%、88.6%、77.6%、79.1%、78.6%。这些成像检查方法(即超声检查、MRI和18F-FDG PET/CT)的诊断能力无显著差异。18F-FDG PET/CT与MRI联合(p = 0.0002)或超声检查联合(p < 0.0001)时,诊断能力显著提高。18F-FDG PET/CT与超声检查联合的诊断能力与三种检查方法联合(18F-FDG PET/CT+超声检查+MRI)相似(p = 0.05)。
在乳腺癌患者中,18F-FDG PET/CT检测腋窝淋巴结转移的诊断性能与超声检查或MRI无显著差异。与单独的18F-FDG PET/CT相比,18F-FDG PET/CT与超声检查或MRI联合可提高诊断性能。